$90 a share on COVID ARDS Authorization ?, page-206

This stock is only high risk for those entering expecting to make millions within weeks.
i have been following MSB for 3 years, going over their studies with multiple friends of mine in different fields (medical, analysts, engineers) who are also interested in stocks (bt specifically) and we all conclude that

1. The treatment works
2. The price is grossly undervalued
3. It's a matter of WHEN not IF

Along with the fact Novartis still hasn't said no, of which if they were, would've already said so
upon novartis' formal agreement we can see this stock reach 10-20$AUD
upon COVID EUA, we can see this stock reach 90$ within a year given the manufacturing upramping happens.
and then, the domino effect, LBP, CHF, GVHD each will see a noticeable jump in the SP.


MSB just need one approval, the rest will fall into place